Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine
1998

Exploiting Tumor Hypoxia with Tirapazamine

Sample size: 37 publication Evidence: moderate

Author Information

Author(s): JM Brown

Primary Institution: Mayer Cancer Biology Laboratory, Department of Radiation Oncology, Stanford University School of Medicine

Hypothesis

Can tirapazamine effectively target hypoxic tumor cells and enhance the efficacy of cisplatin?

Conclusion

Tirapazamine can turn the low oxygen levels in solid tumors from a disadvantage into an advantage by selectively killing hypoxic tumor cells.

Supporting Evidence

  • Tirapazamine selectively kills hypoxic tumor cells without increasing the toxicity of cisplatin.
  • Approximately 70% of tumors had lower oxygen levels than normal tissues.
  • Tirapazamine's effectiveness is independent of the p53 status of the tumor cells.

Takeaway

Tirapazamine is a special medicine that can kill cancer cells that don't have enough oxygen, making it work better with another medicine called cisplatin.

Methodology

The study involved measuring oxygen levels in tumors from patients with squamous cell cancer using a polarographic needle electrode.

Limitations

No clinical trials have been conducted to confirm the effects of tirapazamine with chemotherapy.

Participant Demographics

Patients with squamous cell cancer of the head and neck.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication